Skip to content

Exelixis EXEL Work in process

Work in process at other companies

Eli Lilly logo
Eli LillyLLY
Pfizer logo
PfizerPFE
Incyte logo
IncyteINCY
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX

Other financials

Income statement

See full
Revenue$610.8M+10.0%
Gross profit$590.9M+10.2%
Operating income$251.3M+34.5%
Net income$210.5M+31.9%
EPS (diluted)$0.79+43.6%

Balance sheet

See full
Cash & equivalents$226.2M+23.1%
Total debt$169.5M-9.4%
Total equity$1.9B-9.2%
Total assets$2.6B-8.6%

Cash flow

See full
Operating cash flow$251.8M+19.1%
CapEx$1.5M-48.9%
Free cash flow$250.3M+20.1%

Valuation

See full
Market cap$13.05B+10.1%
Enterprise value$12.99B+9.5%
P/E15.7×-2.8×
P/S5.5×+0.3×

Profitability

See full
Gross margin96.4%-0.3pp
Operating margin39.4%+6.3pp
Net margin35.1%+7.1pp
FCF margin38.6%+2.9pp

Returns & leverage

See full
Return on equity41%+10.8pp
Debt / equity0.1×0.0×
Current ratio3.3×-0.2×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:InventoryWorkInProcess.

The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exelixis's work in process.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Exelixis's work in process?
Exelixis (EXEL) reported work in process of $51.87M in Q1 2026.
How has Exelixis's work in process changed year-over-year?
Exelixis's work in process decreased by 10.4% year-over-year, from $57.9M to $51.87M.
What is the long-term trend for Exelixis's work in process?
Over 5 years (2020 to 2025), Exelixis's work in process has grown at a 21.0% compound annual growth rate (CAGR), from $20.61M to $53.53M.